Scientists from CSIRO, Australia's national science agency, in partnership with Queensland University of Technology, have used artificial intelligence to develop a world-first benchmark for measuring brain atrophy—or thinning—in ...
Feb 1, 2023
0
7
Newborn screening (NBS) for spinal muscular atrophy (SMA), when combined with early treatment, results in better movement ability in affected children, including the ability to walk, when compared to children who are diagnosed ...
Jan 18, 2023
0
15
A new research paper titled "White matter hyperintensity load is associated with premature brain aging" has been published in Aging.
Dec 22, 2022
0
9
A number of new neurologic medications for diseases like multiple sclerosis (MS), Parkinson's disease and migraine have received U.S. Food and Drug Administration (FDA) approval over the past decade. However, with most having ...
Nov 30, 2022
0
2
Adopting some of the strategies behind successfully treating the childhood disease spinal muscular atrophy may enable development of therapies to curb the muscle decline that accompanies aging, new research suggests.
Nov 15, 2022
0
13
For people with multiple sclerosis (MS), hearing a doctor tell them they are experiencing brain atrophy—an important, predictive biomarker of MS disease progression—can trigger debilitating fear and anxiety.
Nov 14, 2022
0
5
Spinal muscular atrophy (SMA), the most common form of neurodegenerative disease in childhood, is caused by defects in the SMN1 gene. SMA patients potentially benefit from three recently approved disease-modifying therapies. ...
Nov 7, 2022
0
14
There are numerous severe, difficult-to-treat monogenetic diseases that are caused by a defect in a single gene—also in the liver. These include the blood coagulation disorders hemophilia A or B or the metabolic disease ...
Oct 26, 2022
0
12
Thalamic atrophy needs to be considered in clinical studies of the functional abilities of individuals with multiple sclerosis, according to findings reported by a team of experts. The article, "Thalamic atrophy moderates ...
Sep 19, 2022
0
7
Two children who received Zolgensma, a gene therapy produced by Swiss drugmaker Novartis to treat spinal muscular atrophy, have died from liver failure, the company said Friday.
Aug 12, 2022
0
13
